Cargando…

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

Cancer is a complex genetic and epigenetic-based disease that has developed an armada of mechanisms to escape cell death. The deregulation of apoptosis and autophagy, which are basic processes essential for normal cellular activity, are commonly encountered during the development of human tumors. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Mrakovcic, Maria, Kleinheinz, Johannes, Fröhlich, Leopold F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567317/
https://www.ncbi.nlm.nih.gov/pubmed/31096697
http://dx.doi.org/10.3390/ijms20102415
_version_ 1783427049314058240
author Mrakovcic, Maria
Kleinheinz, Johannes
Fröhlich, Leopold F.
author_facet Mrakovcic, Maria
Kleinheinz, Johannes
Fröhlich, Leopold F.
author_sort Mrakovcic, Maria
collection PubMed
description Cancer is a complex genetic and epigenetic-based disease that has developed an armada of mechanisms to escape cell death. The deregulation of apoptosis and autophagy, which are basic processes essential for normal cellular activity, are commonly encountered during the development of human tumors. In order to assist the cancer cell in defeating the imbalance between cell growth and cell death, histone deacetylase inhibitors (HDACi) have been employed to reverse epigenetically deregulated gene expression caused by aberrant post-translational protein modifications. These interfere with histone acetyltransferase- and deacetylase-mediated acetylation of both histone and non-histone proteins, and thereby exert a wide array of HDACi-stimulated cytotoxic effects. Key determinants of HDACi lethality that interfere with cellular growth in a multitude of tumor cells are apoptosis and autophagy, which are either mutually exclusive or activated in combination. Here, we compile known molecular signals and pathways involved in the HDACi-triggered induction of apoptosis and autophagy. Currently, the factors that determine the mode of HDACi-elicited cell death are mostly unclear. Correspondingly, we also summarized as yet established intertwined mechanisms, in particular with respect to the oncogenic tumor suppressor protein p53, that drive the interplay between apoptosis and autophagy in response to HDACi. In this context, we also note the significance to determine the presence of functional p53 protein levels in the cancer cell. The confirmation of the context-dependent function of autophagy will pave the way to improve the benefit from HDACi-mediated cancer treatment.
format Online
Article
Text
id pubmed-6567317
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65673172019-06-17 p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death Mrakovcic, Maria Kleinheinz, Johannes Fröhlich, Leopold F. Int J Mol Sci Review Cancer is a complex genetic and epigenetic-based disease that has developed an armada of mechanisms to escape cell death. The deregulation of apoptosis and autophagy, which are basic processes essential for normal cellular activity, are commonly encountered during the development of human tumors. In order to assist the cancer cell in defeating the imbalance between cell growth and cell death, histone deacetylase inhibitors (HDACi) have been employed to reverse epigenetically deregulated gene expression caused by aberrant post-translational protein modifications. These interfere with histone acetyltransferase- and deacetylase-mediated acetylation of both histone and non-histone proteins, and thereby exert a wide array of HDACi-stimulated cytotoxic effects. Key determinants of HDACi lethality that interfere with cellular growth in a multitude of tumor cells are apoptosis and autophagy, which are either mutually exclusive or activated in combination. Here, we compile known molecular signals and pathways involved in the HDACi-triggered induction of apoptosis and autophagy. Currently, the factors that determine the mode of HDACi-elicited cell death are mostly unclear. Correspondingly, we also summarized as yet established intertwined mechanisms, in particular with respect to the oncogenic tumor suppressor protein p53, that drive the interplay between apoptosis and autophagy in response to HDACi. In this context, we also note the significance to determine the presence of functional p53 protein levels in the cancer cell. The confirmation of the context-dependent function of autophagy will pave the way to improve the benefit from HDACi-mediated cancer treatment. MDPI 2019-05-15 /pmc/articles/PMC6567317/ /pubmed/31096697 http://dx.doi.org/10.3390/ijms20102415 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mrakovcic, Maria
Kleinheinz, Johannes
Fröhlich, Leopold F.
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
title p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
title_full p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
title_fullStr p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
title_full_unstemmed p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
title_short p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
title_sort p53 at the crossroads between different types of hdac inhibitor-mediated cancer cell death
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567317/
https://www.ncbi.nlm.nih.gov/pubmed/31096697
http://dx.doi.org/10.3390/ijms20102415
work_keys_str_mv AT mrakovcicmaria p53atthecrossroadsbetweendifferenttypesofhdacinhibitormediatedcancercelldeath
AT kleinheinzjohannes p53atthecrossroadsbetweendifferenttypesofhdacinhibitormediatedcancercelldeath
AT frohlichleopoldf p53atthecrossroadsbetweendifferenttypesofhdacinhibitormediatedcancercelldeath